Supplementary Table S2 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: 59 probesets from an analysis of blood These are probesets for which the null hypothesis was rejected and the change over time averaged over treatment groups was {greater than or equal to}1.2-fold.
Authors: Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361920983